Preparation of Epidermal Growth Factor Conjugates Aimed for Boron Neutron Capture Therapy
Certain tumour cells, such as gliomas, melanomas and squamous carcinomas has increased numbers of epidermal growth factor receptors per cell, due to gene amplification or increased transcription rates1–3. These receptors could be used as targets for therapy with epidermal growth factor, EGF, conjugated with toxic agents. The numbers of receptors in normal cells are ranging from 0 to 104, but in the mentioned tumour cells the number can be highly increased. Growth factors carrying toxic agents could, due to its size, be better than antibodies at penetrating tumour tissues. The toxic agents could be radioactive nuclides, stable nuclides suitable for neutron capture or toxins. EGF, consisting only a 53 amino acid sequence and a molecular weight of about 6 kDa, has a compact and very stable structure. In earlier studies EGF has been modified without destruction of its biological activity or specificity to the receptor4–6.
KeywordsBoron Atom Toxic Agent Boron Neutron Capture Therapy Allyl Bromide Coupling Buffer
Unable to display preview. Download preview PDF.
- 2.J. Mendelsohn. Growth factor receptors as targets for anti-tumour therapy with monoclonal antibodies. Monoclonal antibody therapy 45: 147–160, 1988.Google Scholar
- 3.V.P. Collins, and C.D. James. Gene and chromosomal alterations associated with the development of human gliomas. F4SEB J. 7: 926–930, 1993.Google Scholar
- 10.P. Lindström, P. Olsson, J. Malmqvist, J. Pettersson, P. Lemmen, B. Werner, S. Sjöberg, A. Olin, and J. Carlsson. New carborane-based compounds for boron neutron capture therapy: binding and toxicity of ANC-1, DAC-I and B-Et-I 1-OMe in cultured human glioma and mouse melanoma cells. Anti-Cancer Drugs 5: 43–52, 1994.PubMedCrossRefGoogle Scholar